249 results on '"Damato, Valentina"'
Search Results
2. Clinical, neurophysiological and serological clues for the diagnosis of neuromyotonia and distinction from cramp-fasciculation syndrome
3. Safety and effectiveness of the booster dose of mRNA COVID-19 vaccines in people with multiple sclerosis: A monocentric experience
4. Leptomeningeal enhancement in multiple sclerosis: a focus on patients treated with hematopoietic stem cell transplantation
5. Comparison of Fixed and Live Cell-Based Assay for the Detection of AChR and MuSK Antibodies in Myasthenia Gravis
6. Acetylcholine receptor antibody positivity rate in ocular myasthenia gravis: a matter of age?
7. Benefit and danger from immunotherapy in myasthenia gravis
8. An insight into the mechanical properties of selected commercial oil and alkyd paint films containing cobalt blue
9. Myasthenia Gravis and Related Disorders
10. List of Contributors
11. Conventional and emerging treatments and controversies in myasthenia gravis
12. Epidemiology of Antibody-positive Myasthenia Gravis in Sardinia, Italy (P2-5.027)
13. Immunological response after SARS-CoV-2 infection and mRNA vaccines in patients with myasthenia gravis treated with Rituximab
14. Disease specific enrichment of circulating let-7 family microRNA in MuSK + myasthenia gravis
15. Hematopoietic Stem Cell Transplantation for the Treatment of Autoimmune Neurological Diseases: An Update
16. Efficacy and safety of rituximab in myelin oligodendrocyte glycoprotein antibody-associated disorders compared with neuromyelitis optica spectrum disorder: a systematic review and meta-analysis
17. Comparison of Fixed and Live Cell-Based Assay for the Detection of AChR and MuSK Antibodies in Myasthenia Gravis
18. Association Between a Distinctive Autoantibody-Associated Brainstem Sensory Syndrome and Immune Checkpoint Inhibitors
19. Long-term-video monitoring EEG and 18F-FDG-PET are useful tools to detect residual disease activity in anti-LGI1-Abs encephalitis: A case report
20. Serological and experimental studies in different forms of myasthenia gravis
21. Clinical and immunological characteristics of the spectrum of GFAP autoimmunity: a case series of 22 patients
22. Myasthenia gravis with antibodies to MuSK: an update
23. 275th ENMC international workshop: Seronegative myasthenia gravis: An update paradigm for diagnosis and management, 9–11 February 2024, Hoofddorp, the Netherlands
24. Clinical value of cell-based assays in the characterisation of seronegative myasthenia gravis
25. Safety profile of SARS-CoV-2 vaccination in patients with antibody-mediated CNS disorders
26. Rituximab abrogates aquaporin-4–specific germinal center activity in patients with neuromyelitis optica spectrum disorders
27. Clinical features and outcome of patients with autoimmune cerebellar ataxia evaluated with the Scale for the Assessment and Rating of Ataxia
28. Pattern of ocular involvement in myasthenia gravis with MuSK antibodies
29. Remission of myasthenia gravis with MuSK antibodies during ruxolitinib treatment
30. Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis
31. Distinct lymphocytes subsets in IgM-related neuropathy: clinical-immunological correlations
32. Safety and tolerability of SARS‐Cov‐2 vaccination in patients with myasthenia gravis: A multicenter experience
33. Cervical lymph nodes and ovarian teratomas as germinal centres in NMDA receptor-antibody encephalitis
34. Clinical features and outcome of patients with autoimmune cerebellar ataxia evaluated with the Scale for the Assessment and Rating of Ataxia
35. Efficacy and safety of rituximab in myelin oligodendrocyte glycoprotein antibody- associated disorders compared with neuromyelitis optica spectrum disorder: a systematic review and metaanalysis.
36. B cell related predictive biomarkers of treatment response in myasthenia gravis
37. Demographic changes in myasthenia gravis over the last 20 years: A single center experience
38. Teaching Video NeuroImage: The "Chameleon Eyes Sign" in Myasthenia Gravis.
39. Myasthenia gravis associated with anti‐MuSK antibodies developed after SARS‐CoV‐2 infection
40. Distinctive clinical and neuroimaging characteristics of longitudinally extensive transverse myelitis associated with aquaporin-4 autoantibodies
41. Heterogeneity in myasthenia gravis: considerations for disease management
42. Benefit and danger from immunotherapy in myasthenia gravis
43. Human Leukocyte Antigen Class II associations in late-onset Myasthenia Gravis
44. Response to: “MuSK‐positive myasthenia may be triggered not only by SARS‐CoV‐2”
45. Human Leukocyte Antigen Class II associations in late‐onset Myasthenia Gravis
46. Clinical characteristics and outcome of patients with autoimmune encephalitis: clues for paraneoplastic etiology
47. Tissue-Infiltrating Lymphocytes Analysis Reveals Large Modifications of the Duodenal “Immunological Niche” in Coeliac Disease After Gluten-Free Diet
48. Peripheral Nerve Hyperexcitability Syndromes: a Single Center Experience. (P2.2-099)
49. Clinical and immunological characteristics of the spectrum of GFAP autoimmunity: A case series of 22 patients
50. Myasthenia gravis with antibodies to MuSK: an update
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.